Fosfructose (trisodium)

Fosfructose trisodium (Diphosphofructose trisodium, Esafosfan trisodium, FDP trisodium) is a cytoprotective natural sugar phosphate used in research on cardiovascular ischemia, sickle cell anemia, and asthma. Fosfructose trisodium acts by stimulating anaerobic glycolysis, which produces adenosine triphosphate under ischemic conditions^[1][2][3]. IC50 & Target:Endogenous Metabolite^[1] In Vivo:Fosfructose trisodium (500 mg/kg; i.v.; 15-minute infusion before hypothermic circulatory arrest, 30-minute infusion after hypothermic circulatory arrest) administration is associated with an 83.3% 7-day survival rate, improved behavioral recovery, reduced intracranial pressure, lower cardiac and brain injury markers, and significantly reduced histopathologic brain damage in female juvenile native stock pigs subjected to 75 minutes of hypothermic circulatory arrest^[1].
Fosfructose trisodium (50-200 mg/g; oral; continuous feeding in artificial diet) enhances glycolysis in Hyphantria cunea larvae, induces 100% corrected mortality at doses of 50, 100, and 200 mg/g with dose-dependent speed, restricts larval growth and development, and disrupts chitin biosynthesis by altering pathway gene expression and tissue chitin levels^[2].